Primary source: R1 via GlobeNewswire, November 9, 2026, 8:00 a.m. ET
On November 9, 2026, R1 announced an 11-year renewal of its partnership with Ascension, effective through fiscal year 2037. The release says the renewal follows Ascension’s enterprise-wide adoption of Phare OS, R1’s Revenue Operating System. Financial terms were not disclosed. RevCycleAI is not estimating them.
That is the term in the release: an 11-year renewal, effective through fiscal year 2037. The release does not state a start date, define when Ascension’s fiscal year ends, name a price, or give a net-patient-revenue figure for the book under the agreement.
The item is datelined Chicago, November 9, 2026, and timed at 8:00 a.m. ET on GlobeNewswire. The source line is R1 RCM Holdco Inc. The release’s own subhead says the long-term agreement supports Ascension’s efforts to simplify the financial experience for patients, reduce administrative demands, and give care teams more time to focus on those they serve. That is the stated purpose. It is not a measured result.
Becker’s Hospital Review published a same-day report at the URL cited below. A direct request for that page returned 403. A search excerpt of the same URL restates the 11-year term through fiscal 2037, the Phare OS adoption, Saurabh Tripathi’s quote, and R1’s company scale figures, which the excerpt attributes to the release. The excerpt also describes Ascension as St. Louis-based. The GlobeNewswire release opened for this article does not state a headquarters city. The full Becker’s body was not opened, so no figure in this article is attributed to Becker’s beyond that excerpt.
| Element | What the November 9 release says |
|---|---|
| Parties | R1 and Ascension. R1 describes itself as the leader in healthcare revenue management, and Ascension as one of the nation’s leading faith-based, nonprofit health systems. Both descriptions are the release’s. |
| Event | An 11-year renewal of the partnership, not a sale of either company. |
| Term | Effective through fiscal year 2037. No start date and no fiscal-year calendar are stated. |
| Technology | Follows Ascension’s enterprise-wide adoption of Phare OS. Joe Flanagan, R1’s chief executive, says Phare OS is fully deployed. |
| What Phare OS prioritizes | In the About section, R1 calls Phare OS the industry’s first Healthcare Revenue Operating System and a comprehensive automation platform that prioritizes pre-bill workflows for authorization, utilization review, documentation and coding. |
| Performance | R1 says Ascension has begun realizing financial and operational benefits, including “top-quartile industry performance across a broad set of key measures.” No measure is named. |
| Economics | Not disclosed. No contract value, fee structure, or savings figure. |
The release does not give a contract value, a pricing model, a staffing plan, a facility list, a hospital or physician scope, or a baseline. An 11-year term is not a dollar figure. R1’s company-wide scale, below, is not the value of this renewal. RevCycleAI is not filling either gap.
The operating claim is in the second paragraph. Following Ascension’s enterprise-wide adoption of Phare OS, R1 expects to deliver continued significant value over the term of the agreement. “Expects” is R1’s forecast. The release does not attach a dollar amount to that expectation.
The About section is where R1 defines the product. It says R1 created Phare OS, “the industry’s first Healthcare Revenue Operating System,” and describes it as a comprehensive automation platform that prioritizes pre-bill workflows for authorization, utilization review, documentation and coding “to move revenue forward and drive stronger financial performance.” “Industry’s first” is company language. The workflow list is specific: authorization, utilization review, documentation, and coding. The verb in that sentence is prioritizes.
That verb matters. The Becker’s excerpt says the platform automates those pre-bill workflows. The release says it prioritizes them. This article uses the release. Prioritizing a workflow is not the same statement as running it without a person, and the release does not publish an automation rate for any of the four inside Ascension.
The release says Ascension “has already begun realizing financial and operational benefits from this technology-first approach, including top-quartile industry performance across a broad set of key measures.” R1 does not name the measures, the comparison set, the period, or a single rate. “A broad set of key measures” is not a metric. No denial rate, cost to collect, cash yield, days in accounts receivable, or authorization turnaround time appears in the release.
“Ascension’s decision to extend our partnership through 2037 underscores the meaningful value we have delivered together and reinforces R1’s role as a strategic technology partner for leading healthcare organizations. With Phare OS fully deployed, Ascension is leveraging AI-powered innovation to strengthen financial performance, streamline operations and build a more intelligent revenue cycle for the future.” — Joe Flanagan, chief executive officer, R1. Verbatim from the release.
“Our focus is on making healthcare easier for patients and giving our teams more time to focus on what matters most. By using technology to reduce administrative burden and improve how we operate, we can direct more time and resources toward caring for patients and better serving the communities that depend on us.” — Saurabh Tripathi, chief financial officer, Ascension. Verbatim from the release.
Flanagan’s “fully deployed” is a deployment statement. The paragraph after the quotes says Ascension has begun realizing benefits, and that R1 and Ascension will continue supporting Ascension’s efforts to improve processes and services through technology and automation. A system can be called fully deployed and still be in a program of improvement. The release does not say which of those two sentences describes authorization, which describes coding, or which describes cash.
Tripathi’s statement is about administrative burden, time, and communities. It does not state a financial target, a headcount change, or a patient-liability policy. The release’s earlier line, that the agreement reflects a continued focus on using technology to reduce administrative complexity, is the same theme. It is not a staffing plan.
The About section says R1 combines more than 20 years of revenue cycle expertise with enterprise-grade AI and automation. It says R1 partners with 1,000 healthcare providers, including 95 of the top 100 U.S. health systems, and processes more than 1.2 billion payer transactions annually. It says that scale provides unmatched operational insight. Every one of those figures, and the word unmatched, is R1’s description of R1. None of them is Ascension’s net patient revenue, Ascension’s transaction count, or the price of an 11-year renewal.
The same section states R1’s mission as making healthcare work better for all. That is a mission line. The contact on the release is Mike Gilhooly, director of public relations and communications, at media@r1rcm.com.
This renewal is a term decision about a platform R1 has already been describing as pre-bill. It is not a new product launch, and it is not evidence that earlier product claims have been scored at Ascension.
On August 18, 2026, RevCycleAI covered R1’s announcement that it would acquire Humata Health and place prior-authorization automation inside Phare OS. That article is about the Humata agreement. Its performance figures are not Ascension results, and they are not repeated here as results of this renewal.
On September 16, 2026, R1 announced Phare Utilization Management as an extension of Phare OS. The coverage treats that as a product launch aimed at medical-necessity risk before the bill. Today’s release names utilization review as one of the four pre-bill workflows Phare OS prioritizes. It does not say Phare UM is the module Ascension is using, and it does not publish an Ascension status-accuracy result.
On October 20, 2026, R1 announced a separate partnership with Fortuna Health around Medicaid enrollment, described as complementing Phare. Commercial terms were not disclosed in that announcement either. The Fortuna article is a different agreement. Nothing in today’s release says the Ascension renewal includes Fortuna.
The news is the term, attached to a platform R1 says is already in place. An 11-year renewal through fiscal 2037, after an enterprise-wide Phare OS adoption, is a decision to keep the operating layer. It is not a disclosed price, and it is not a published scorecard.
Five items decide whether this is an operating change or a term extension. None of them is answered in the release.
One further limit belongs with the term itself. “Through fiscal year 2037” is not a calendar date until someone states when that fiscal year ends. The release does not.
The GlobeNewswire release establishes the parties, the November 9, 2026 announcement, the 11-year renewal through fiscal year 2037, the enterprise-wide Phare OS adoption, Flanagan’s “fully deployed” statement, the two quotes above, the company-reported top-quartile sentence, and R1’s About-section description of pre-bill workflows and company scale. Becker’s excerpt, limited as described above, agrees on the term, the Phare OS adoption, Tripathi’s quote, and the scale figures as coming from the release, and it adds a St. Louis location the release does not.
Neither source, as reviewed here, discloses price, fee design, a start date, a fiscal-year end date, a facility list, a staffing plan, Ascension’s net patient revenue, or any named performance metric behind the quartile claim. This is a partnership renewal. It is not an acquisition, a merger, or a funding round, and it does not belong on the deals and funding tracker on the facts in the release.
Ascension is extending R1 through fiscal 2037, and the release puts Phare OS at the center of that decision. The release supports the renewal, the enterprise-wide adoption, and a chief-executive statement that the platform is fully deployed. It supports a performance claim only as R1’s sentence, with no measures attached.
Revenue-cycle leaders reading this as a market signal should separate those layers. A faith-based nonprofit system that R1 calls one of the nation’s leading, keeping its revenue-cycle partner through fiscal 2037, is the fact. A pre-bill platform covering authorization, utilization review, documentation, and coding is the product description R1 puts in the About section. Top-quartile performance is an assertion that still needs a definition. Until the measures and the economics are public, the announcement is a term extension, not a case study.
Term, platform, and the claims that are still the company’s.
Sources: R1 via GlobeNewswire, “R1 and Ascension Extend Partnership Through 2037 Leveraging Phare OS to Advance a Technology-First Revenue Cycle,” November 9, 2026, 8:00 a.m. ET, Chicago; Becker’s Hospital Review, “Ascension extends R1 revenue cycle partnership through 2037” (page returned 403 on direct fetch; a search excerpt was reviewed and is cited only for what that excerpt states). Quotes from Joe Flanagan and Saurabh Tripathi are verbatim from the GlobeNewswire release. “Top-quartile industry performance,” the 1,000-provider count, the 95-of-top-100 count, the 1.2 billion payer transactions, “more than 20 years,” “industry’s first,” and “unmatched operational insight” are R1’s claims in that release. No contract value was disclosed, and none is estimated. Prior RevCycleAI articles linked above are context for earlier Phare OS announcements. They are not Ascension results.